Silencing of α-N-acetylgalactosaminidase in the gastric cancer cells amplified cell death and attenuated migration, while the multidrug resistance remained unchanged

Cell Biol Int. 2022 Feb;46(2):255-264. doi: 10.1002/cbin.11727. Epub 2021 Nov 29.

Abstract

Although the elevated level of the α-N-acetylgalactosaminidase enzyme (encoded by the NAGA gene) is a well-recognized feature of cancer cells; little research works have been undertaken on the cancer malignancy mechanisms. The effects of NAGA gene downregulation on cancer cells' features such as drug resistance, impaired programmed cell death, and migration were analyzed in this study. The cells grew exponentially with a doubling time of 30 h in an optimal condition. Toxicity of daunorubicin chemotherapy drug on NAGA-transfected EPG85.257RDB cells was evaluated in comparison to control cells and no significant change was recorded. Quantitative transcript analyses and protein levels revealed that the MDR1 pump almost remained unchanged during the study. Moreover, the NAGA gene downregulation enhanced the late apoptosis rate in EPG85.257RDB cells at 24 h posttransfection. The investigated expression level of genes and proteins involved in the TNFR2 signaling pathway, related to cancer cell apoptosis, showed considerable alterations after NAGA silencing as well. MAP3K14 and CASP3 genes were downregulated while IL6, RELA, and TRAF2 experienced an upregulation. Also, NAGA silencing generally diminished the migration ability of EPG85.257RDB cells and the MMP1 gene (as a critical gene in metastasis) expression decreased significantly. The expression of the p-FAK protein, which is located in the downstream of the α2 β1 integrin signaling pathway, was reduced likewise. It could be concluded that despite drug resistance, NAGA silencing resulted in augmentative and regressive effects on cell death and migration.

Keywords: apoptosis; cell adhesion; gene silencing; metastasis; multidrug resistance; α-NaGalase.

MeSH terms

  • Apoptosis
  • Cell Death
  • Cell Line, Tumor
  • Drug Resistance, Multiple
  • Humans
  • Stomach Neoplasms* / metabolism
  • alpha-N-Acetylgalactosaminidase / genetics
  • alpha-N-Acetylgalactosaminidase / metabolism
  • alpha-N-Acetylgalactosaminidase / therapeutic use

Substances

  • NAGA protein, human
  • alpha-N-Acetylgalactosaminidase